SCHEMBL743478

SCHEMBL743478

Cc1cccc(N(C(=O)O)c2ccccc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.45
POLB P06746 2/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 5/20 0.41
NPC1 O15118 4/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GBA1 P04062 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.39
GRM5 P41594 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
P2RX7 Q99572 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.38
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CCR1 P32246 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7982618 0.88 ALDH1A1 (0.49) NPSR1POLBTSHRRAB9ANPC1
SCHEMBL4506327 0.81 POLB (0.44) NPSR1POLBTSHRRAB9ANPC1
SCHEMBL57998 0.81 NPSR1 (0.44) NPSR1POLBTSHRRAB9ANPC1
SCHEMBL743035 0.80 NPSR1 (0.40) NPSR1POLBTSHRRAB9ANPC1
SCHEMBL15174120 0.78 RAB9A (0.43) RAB9ANPC1KMT2AMEN1GBA1
SCHEMBL30811084 0.77 CCR1 (0.43) NPSR1TSHRRAB9ANPC1KMT2A
SCHEMBL60214 0.77 TAS2R14 (0.43) NPSR1POLBRAB9ANPC1KMT2A
SCHEMBL27598433 0.76 CCR1 (0.43) RAB9ANPC1KMT2AMEN1GBA1
SCHEMBL1034457 0.76 ALDH1A1 (0.48) NPSR1POLBTSHRRAB9ANPC1
SCHEMBL2130904 0.76 DHFR (0.47) NPSR1TSHRRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138336-B2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase BAYER HEALTHCARE LLC (US) 2012-03-20 US disclosed
US-20090325956-A1 Aromatic amine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325956-A1 Aromatic amine derivative and use thereof SCD, SCD5, SMS NPSR1 3559/4885POLB 2804/4885TSHR 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.